-Down to Earth Untimely rains have damaged cotton and soyabean crops all over the state As if prevailing drought-like situation and other natural calamities in 2014 were not enough, the low procurement prices for cotton produced in the state are set to destroy the agricultural economy of the state. The state government has started cotton procurement for the season at the dismal minimum support price (MSP) of Rs 4,050 per quintal. This, allegedly,...

-Down to Earth Farmers want drought to be declared; government dilly-dallies According to the second survey carried out by the Revenue Department of Maharashtra, more than 20,000 villages in the state have received less than 50 per cent agricultural yield this year. The state has a total of 43,722 villages. This means that close to half the state is in an agricultural crisis. An earlier survey had put this number at a mere...

-Down to Earth Agricultural markets have turned into centres of political power, say farmers' organisations The new BJP government in Maharashtra has dismissed 166 agricultural produce market committees (APMCs), including the apex Navi Mumbai APMC, following thousands of complaints of irregularities and misconduct received against them. An order to this effect was issued on Monday, November 10, to the director of agricultural marketing in the state. Agriculture Secretary Sudhir Goyal informed that the...

-Down to Earth Study finds that black carbon and ozone pollution in India has significantly cut wheat and rice yield The levels of smog and air pollution in India have become so severe that crop yields are taking a hit. Scientists recently analysed yields for wheat and rice alongside pollution data, and concluded that the crop yields have significantly reduced. They have attributed the decrease in yield to two air pollutants-black carbon...

-Down to Earth Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment. BMS had announced that it would create a tiered pricing strategy for...